SPRY biotech catalysts & pipeline

ARS PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

neffy — Interim data

Q4 2026

The interim analysis population is fully enrolled as of May 2026, and interim data from this clinical trial is anticipated in the fourth quarter of 2026, followed by the potential initiation of a single Phase 3 pivotal efficacy study in mid-2027.

Source filing

intranasal epinephrine — Interim data

Q1 2027

Interim data from Phase 2b trial in chronic spontaneous urticaria (CSU) expected in Q1 2027; no FDA-approved on-demand treatment currently exists for acute CSU flares

Source filing

neffy — Regulatory decision

early 2027

Discussions with additional states are ongoing, and we anticipate a majority of Medicaid state plans adopting neffy to their unrestricted Medicaid formularies by early 2027.

Source filing

Explore the free biotech catalyst calendar